Trials / Terminated
TerminatedNCT00207025
A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical research study is to learn about the safety and tolerability of daily BMS-275183 in patients with advanced cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-275183 |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2007-02-01
- First posted
- 2005-09-21
- Last updated
- 2010-03-02
Locations
3 sites across 2 countries: United States, Belgium
Source: ClinicalTrials.gov record NCT00207025. Inclusion in this directory is not an endorsement.